delavirdine has been researched along with didanosine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Boyle, J; Chaitt, DG; Coleman, S; Cox, SR; Daenzer, CL; Davey, RT; Eastman, PS; Falloon, J; Freimuth, WW; Herpin, BR; Kovacs, JA; Lane, HC; Masur, H; Metcalf, JA; Polis, MA; Reed, GF; Walker, RE; Wathen, L | 1 |
| Cox, SR; DeRemer, M; Driver, M; Fischl, MA; Freimuth, WW; Morse, GD; Shelton, MJ | 1 |
| Berrios, L; Cox, S; Demeter, LM; Dexter, A; Freimuth, W; Gerondelis, P; Meehan, PM; Morse, G; Reichman, RC | 1 |
| Chong, KT; Pagano, PJ | 1 |
| Saag, MS; Schooley, RT | 1 |
| Bassett, R; Connick, E; Demeter, L; Fischl, M; Freimuth, W; Friedland, GH; Griffith, B; Hirsch, M; Hughes, M; Morse, G; Nevin, T; Pollard, R | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Freimuth, WW; Glick, HA; Schulman, KA; Weinfurt, KP; Willke, RJ | 1 |
| Smart, T; Torres, G | 1 |
| Mascolini, M | 1 |
| James, JS | 1 |
| Atkinson, MJ; Frangakis, C; Huang, IC; Lenderking, WR; Willke, RJ; Wu, AW | 1 |
3 review(s) available for delavirdine and didanosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
5 trial(s) available for delavirdine and didanosine
| Article | Year |
|---|---|
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Anti-HIV Agents; Biological Availability; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indoles; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine | 1996 |
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cross-Over Studies; Delavirdine; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV-1; Humans; Indoles; Male; Piperazines | 1997 |
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Safety; Zidovudine | 1999 |
Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; Health Status Indicators; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quality of Life; RNA, Viral; Viral Load | 2000 |
US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Patient Satisfaction; Psychometrics; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Sickness Impact Profile; United Kingdom; United States; Viral Load | 2007 |
15 other study(ies) available for delavirdine and didanosine
| Article | Year |
|---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[A new AIDS drug in evaluation].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine | 1993 |
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Topics: Adult; Anti-HIV Agents; Delavirdine; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phenotype; Piperazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 1997 |
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
Topics: Anti-HIV Agents; Cell Line; Delavirdine; Didanosine; DNA, Viral; HIV-1; Humans; Indoles; Piperazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Antiviral roundup.
Topics: CD4 Lymphocyte Count; Cohort Studies; Delavirdine; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Mutation; Piperazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Zidovudine | 1996 |
FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Didanosine; Disease Progression; Drug Approval; Drug Industry; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load; Zidovudine | 1996 |
Delavirdine (Rescriptor) approved.
Topics: Anti-HIV Agents; Delavirdine; Didanosine; Drug Approval; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |